Safety and Efficacy of Oral GKT137831 in Patient With Type 2 Diabetes and Albuminuria

Key Inclusion Criteria: * Male or female aged 18 to 80 years * History of type 2 diabetes, defined as fasting plasma glucose ≥7.0 mmol/L (126 mg/dL) or a glycated hemoglobin (HbA1c) \>6.5% (48 mmol/mol) on at least 2 occasions prior to screening. * Albuminuria defined as a UACR of 300 to 3500 mg/g. * An eGFR ≥30 mL/min/1.73 m2, as calculated by the CKD-EPI formula. * Must be taking an ACEI or an ARB for at least 6 weeks prior to the first screening visit (Visit 1) and during the screening period. The dose must have been stable for at least 4 weeks prior to the first screening visit (Visit 1). Combination therapy associating an ACEI and an ARB is not permitted. Key Exclusion Criteria: * History of type 1 diabetes * Any other non-diabetic kidney disease(s) except for hypertensive nephropathy which is acceptable. * Diagnostic or interventional procedure requiring a contrast agent within 4 weeks of the first screening visit (Visit 1) or planned during the study. * History of renal transplant or planned renal transplant during the study. * A history of acute renal dialysis or acute kidney injury (defined according to the Kidney Disease: Improving Global Outcomes \[KDIGO\] definition) within 12 weeks of the first screening visit (Visit 1) * HbA1c level \>11% (97 mmol/mol). * History of hypothyroidism requiring hormone replacement therapy. * History of active cardiovascular disease * A personal or family history of long QT syndrome. * Administration of any investigational product within 30 days or within 5 half-lives of the investigational agent